A Phase 4 interventional study of Clomiphene Citrate 100 mg and Sildenafil Citrate 25Mg Tab in Polycystic Ovarian Syndrome (PCOS) and Polyendocrine Metabolic Ovarian Syndrome (PMOS), sponsored by Nishtar Medical University. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Nishtar Medical University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Polycystic Ovary Syndrome with a site in Pakistan — 7 open to participants now, 10 under way, none of them phase 3. Polycystic Ovary Syndrome · Pakistan.
Among the 40 studies in Polycystic Ovary Syndrome with a site in Pakistan, this one is the 13th largest by enrollment of the 39 interventional ones that give a count, is one of 11 that started in 2025, is one of 2 in phase 4, and was the 35th registered.
958 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →7 of the 40 studies in Polycystic Ovary Syndrome with a site in Pakistan are open now. Recruiting first, the newest first:
Khyber Medical University Peshawar · Sites in Pakistan
Ages 18–45 · Women only
Riphah International University · Sites in Pakistan
Ages 18–35 · Women only
Riphah International University · Sites in Pakistan
Ages 18–35 · Women only
Riphah International University · Sites in Pakistan
Ages 18–35 · Women only
Quaid-e-Azam Medical College · Sites in Pakistan
Ages 18–35 · Women only
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 3 · Phase 4 2
First in 2016; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 70 across 699 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 70 across the 39 interventional studies, 180 across the 1 observational. Of the 29 that completed or were terminated, 2 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 40 has an industry lead sponsor. The 10 most frequent:
Nishtar Medical University is the lead sponsor of 30 studies on the registry; 9 are open to participants now.
Nishtar Medical University has 3 studies filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Polycystic Ovary Syndrome with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07629895Quaid-e-Azam Medical CollegeMyo-Inositol Alone Versus Myo-Inositol Plus Alpha-Lactalbumin in Women With Polycystic Ovary Syndrome | 2027-04 |
| NCT07875400Riphah International UniversityHigh Intensity Interval Training Versus Mat Pilates in Women With PCOS | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies in Polycystic Ovary Syndrome with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this randomized clinical trial is to compare the effectiveness of clomiphene citrate alone with clomiphene citrate combined with sildenafil citrate for inducing ovulation and achieving pregnancy in women with polycystic ovary syndrome (PCOS) who have difficulty becoming pregnant.
The main question the study aims to answer is:
Does adding sildenafil citrate to clomiphene citrate increase the chance of ovulation and pregnancy compared with clomiphene citrate alone in women with PCOS?
The study will include 98 women aged 18-45 years with PCOS and a history of difficulty achieving pregnancy for more than 2 years. Participants will be randomly assigned to one of two groups.
Treatment will be given for 12 weeks. Participants will be assessed for ovulation, pregnancy, and endometrial thickness. Ovulation will be assessed using transvaginal ultrasound and/or a blood progesterone test. Pregnancy will be assessed using a urine pregnancy test and/or ultrasound.
The primary hypothesis is that women receiving clomiphene citrate plus sildenafil citrate will have a higher rate of pregnancy than women receiving clomiphene citrate alone. The study will also determine whether adding sildenafil improves ovulation and endometrial thickness.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Oral Clomiphene Citrate and Sildenafil Citrate will be given to participants in this Arm
Drug: Clomiphene Citrate 100 mg · Drug: Sildenafil Citrate 25Mg Tab
Participants in this arm will be given clomiphene citrate and placebo
Drug: Clomiphene Citrate 100 mg · Drug: Placebo
Clomiphene citrate 100 mg administered orally once daily from menstrual cycle days 3-7 for ovulation induction. Treatment will be repeated for 12 weeks.
Sildenafil citrate 25 mg administered orally twice daily from menstrual cycle days 8-12, in addition to clomiphene citrate, for ovulation induction. Treatment will be repeated for 12 weeks.
Matching placebo containing starch administered orally twice daily from menstrual cycle days 8-12, in addition to clomiphene citrate. Treatment will be repeated for 12 weeks.
Pregnancy
Pregnancy will be considered achieved when a urine human chorionic gonadotropin (hCG) test is positive after 7 days of a missed menstrual period and/or a gestational sac is detected by ultrasound.
Time frame: From initiation of treatment (1st cycle) through completion of third treatment cycle, up to 12 weeks
Ovulation
Ovulation will be considered present when a collapsed follicle and free fluid in the pouch of Douglas are observed on transvaginal ultrasound and/or serum progesterone is ≥3 ng/mL. Transvaginal ultrasound will be start around cycle day 10-12, then repeat every 1-2 days until evidence of ovulation. Serum progesterone will be measured approximately 7 days after the expected ovulation (often around cycle day 21 in a 28-day cycle).
Time frame: From initiation of treatment (first cycle) through completion of the third cycle, up to 12 weeks
Endometrial Thickness
Endometrial thickness will be measured by transvaginal ultrasonography once during each treatment cycle, at the peri-ovulatory assessment when the dominant follicle reaches approximately 18-22 mm in diameter, before evidence of follicular rupture. Measurements will therefore be obtained during each of the three treatment cycles.
Time frame: From initiation of treatment (first cycle) through completion of the third cycle, up to 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Dec 2025, 5 months.
Of 41 non-industry phase 4 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 45. This study's 5 months is below that.
Counting every sponsor, half of 42 studies reached it within 25 months; a quarter within 11 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Nishtar Medical University